Clinical Trial

Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

Name: Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial — clinical trial record (NCT07722754)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BOND-4

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Primary endpoint: objective response rate Secondary endpoints: PFS, OS and adverse events

Trial Details

NCT Number	NCT07722754
Lead Sponsor	Guangdong Provincial People's Hospital
Conditions	Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Enrollment	160 participants
Start Date	2026-08-01
Primary Completion	2028-07-31 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-23